Compare prices and buy Survodutide from 12 research peptide vendors - also called suppliers or sources. Updated daily.
An acylated dual agonist of the glucagon and GLP-1 receptors (CAS 2805997-46-8), built on a 29-residue glucagon-based chain and developed by Boehringer Ingelheim under license from Zealand Pharma as BI 456906. The glucagon-receptor arm targets hepatic fat and energy expenditure alongside GLP-1-driven appetite effects. Has received FDA Breakthrough Therapy designation for non-cirrhotic MASH with stage 2 or 3 fibrosis, and is in Phase 3 trials but not approved in any market.
For research purposes only. Not medical advice.
Survodutide (Boehringer Ingelheim's BI 456906) is a synthetic peptide that activates the glucagon receptor and the GLP-1 receptor, the target of semaglutide. It was discovered at Zealand Pharma and licensed to Boehringer, which runs its development and commercialization alone. Its registered structure (FDA GSRS, UNII 2ALA66NS64) is a 29-residue chain built on the glucagon sequence, with a C18 fatty diacid attached through a short linker. The fatty acid binds albumin and extends its half-life.
Boehringer's 2022 discovery paper frames the design around oxyntomodulin, the gut hormone that activates both receptors and lowers body weight in humans by raising energy expenditure as well as reducing food intake. Retatrutide adds GIP-receptor activity to the same pair.
The glucagon arm is also why survodutide is developed for liver disease. Glucagon receptors are concentrated in the liver, and Boehringer attributes reductions in liver fat, inflammation and fibrosis to direct action there. A 2026 post hoc analysis of the Phase 2 MASH trial (Hepatology) estimated that weight reduction mediated about two-thirds of the effect on MASH resolution but only about a third of the effect on fibrosis improvement.
Boehringer's figures under the efficacy estimand, which assumes participants stayed on treatment, were up to 16.6% versus 3.2% in SYNCHRONIZE-1 and up to 13.1% versus 3.1% in SYNCHRONIZE-2, where HbA1c fell by up to 1.21 points from a 7.4% baseline.
Gastrointestinal events were the most common adverse effects. In SYNCHRONIZE-2, 18% of survodutide participants discontinued because of them, versus 1.2% on placebo, mostly during dose escalation. Boehringer says its later trials allow more flexible escalation.
Several Phase 3 trials are still running: SYNCHRONIZE-CVOT (cardiovascular safety, about 4,935 participants planned), LIVERAGE (MASH with fibrosis stages F2 to F3) and LIVERAGE-Cirrhosis (compensated MASH cirrhosis). In October 2026 Boehringer said it expected to present SYNCHRONIZE-CVOT results later that year.
Survodutide is not approved in any market. The FDA granted it Fast Track designation in May 2021 and Breakthrough Therapy designation in September 2024, both for non-cirrhotic MASH with moderate or advanced fibrosis. Breakthrough designation brings closer FDA guidance and can speed review, and it is not an approval.
As an investigational compound with no USP monograph and no approved product containing it, survodutide is not eligible for compounding by a 503A pharmacy or a 503B outsourcing facility. The FDA bulk-substance proceedings that decide the status of older research peptides do not reach it.
Mazdutide, from Eli Lilly and Innovent Biologics, has been approved in China since June 2025, which Innovent describes as the first approval of a GLP-1/glucagon dual agonist for weight management. The two share a mechanism but are distinct molecules: survodutide is a 29-residue chain carrying a C18 fatty diacid, mazdutide a 34-residue chain carrying a C20 diacid. Mazdutide's Phase 3 trials enrolled Chinese adults over shorter periods than SYNCHRONIZE, so the two programs' weight-loss figures are not directly comparable.
No. Survodutide is investigational and not approved in any market. The FDA granted it Breakthrough Therapy designation in September 2024 for non-cirrhotic MASH with moderate or advanced fibrosis, which can speed review but is not an approval. Boehringer Ingelheim reported Phase 3 obesity results from SYNCHRONIZE-1 and SYNCHRONIZE-2 in 2026, and trials in MASH and cardiovascular safety are ongoing. Research-grade survodutide sold by peptide vendors is for laboratory research only, not for human consumption.
Survodutide activates the glucagon receptor, which is concentrated in the liver, as well as the GLP-1 receptor. In a 48-week Phase 2 trial published in the New England Journal of Medicine in 2024, MASH improved without worsening of fibrosis in 43% to 62% of participants receiving survodutide versus 14% with placebo. Two Phase 3 trials, LIVERAGE and LIVERAGE-Cirrhosis, are testing it in MASH with fibrosis and in compensated MASH cirrhosis.
Survodutide was discovered at Zealand Pharma and licensed to Boehringer Ingelheim, which is solely responsible for its development and commercialization worldwide. Its development code is BI 456906, and Boehringer runs its Phase 3 programs, SYNCHRONIZE in obesity and LIVERAGE in MASH.
The two share a mechanism, activating both the GLP-1 and glucagon receptors, but they are distinct molecules. Survodutide is a 29-residue chain carrying a C18 fatty diacid and is not approved anywhere. Mazdutide, from Eli Lilly and Innovent Biologics, is a 34-residue chain carrying a C20 fatty diacid and has been approved in China since 2025. Their trials enrolled different populations for different durations, so their weight-loss figures are not directly comparable.
Survodutide is sold by 12 research peptide vendors indexed on PeptideScouter, with 15 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
11 of the 12 indexed vendors currently have Survodutide in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Glacier Aminos currently lists Survodutide at $4.35/mg, the lowest listed price across 12 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $3.92/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 12 vendors listing Survodutide publish a PeptideScouter code, worth 10% to 15% off. Applied, the lowest effective price falls from $4.35/mg listed to $3.92/mg at Glacier Aminos. Each vendor's code is shown beside its price in the table above.
Survodutide ranges from $4.35/mg to $16.67/mg across 15 listings from 12 research peptide vendors, normalized to USD per milligram and refreshed daily.
12 research peptide vendors currently list Survodutide on PeptideScouter, with 11 in stock right now. We track 15 listings across size and kit variants.
Survodutide's CAS Registry Number is 2805997-46-8.
